PLATINUM-RESISTANT OVARIAN CANCER

This early-phase study tests a new treatment called CIML NK cell therapy for people with recurrent ovarian cancer that no longer responds to platinum-based chemotherapy. The therapy uses specially trained natural killer cells from a donor to attack the cancer. The study aims to f…

This early-phase study tests a new drug called HWK-016 in people with advanced ovarian or endometrial cancers that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to find the safest d…

This early-stage study tests a new drug called HWK-007 in people with advanced solid tumors, such as certain ovarian, endometrial, and lung cancers. The drug is designed to target and attack cancer cells that have a specific marker (PTK7). The main goals are to find the safest do…

This study tests whether a cancer-killing virus (Olvi-Vec) given into the abdomen can make platinum-resistant ovarian cancer respond to chemotherapy again. About 186 women whose cancer has not responded to at least three prior treatments will receive either Olvi-Vec plus chemo an…

This study tests a new drug called IN10018 combined with standard chemotherapy for women with a type of ovarian cancer that no longer responds to platinum-based treatments. About 150 adults will take part to see if the combination is safe and shrinks tumors. The goal is to find a…

This study tests a new treatment for people with ovarian cancer that no longer responds to platinum-based chemotherapy. The approach combines a patient's own immune cells (M-CENK) with a drug that boosts them (N-803) and a chemotherapy drug (gemcitabine). The goal is to see if th…

This early-phase trial tests an experimental drug called MOv18 IgE in people with advanced ovarian, endometrial, or triple-negative breast cancers that have high levels of a protein called folate receptor alpha. The study has two parts: first, finding a safe dose, and then checki…

This early-stage trial tests a new drug called MEN2501 in about 100 adults with ovarian cancer that has stopped responding to platinum-based chemotherapy. The main goals are to find a safe dose and check for side effects. Researchers will also watch for any signs that the drug sh…

This study tests a new drug called CBX-12 in 40 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if the drug can shrink tumors and to check its safety at two different dose levels. Participants receive the drug once every 21 days.

This early-phase study tests an experimental pill, NKT3964, designed to break down a protein (CDK2) that helps cancer cells grow. About 150 adults with advanced or metastatic solid tumors (including ovarian, endometrial, breast, gastric, and lung cancers) that have stopped respon…

This early-phase trial tests a one-time treatment called OPB-101 for people with ovarian cancer that no longer responds to platinum chemotherapy. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals are to ch…

This early-phase study tests a new drug called CTIM-76 in people with ovarian, testicular, or endometrial cancer that has come back or stopped responding to standard treatments. The drug works by helping the immune system attack cancer cells that have a specific marker called CLD…

This study is testing an experimental drug called MGC026 in about 250 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Participants receive the drug by IV and are closely monitore…

This study tests an experimental drug called lorigerlimab in about 60 people with advanced ovarian or other gynecologic cancers that no longer respond to standard chemotherapy. Participants receive the drug by IV every 3 weeks. The goal is to see if the drug can shrink tumors and…